Compounds > pomalidomide
Page last updated: 2024-09-04

pomalidomide and melflufen

pomalidomide has been researched along with melflufen in 3 studies

Compound Research Comparison

Studies
(pomalidomide)		Trials
(pomalidomide)		Recent Studies (post-2010)
(pomalidomide)		Studies
(melflufen)		Trials
(melflufen)		Recent Studies (post-2010) (melflufen)
62312155231631

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P1
Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M1
Abdulhaq, H; Bakker, NA; Dimopoulos, MA; Hájek, R; Ludwig, H; Mateos, MV; Norin, S; Richardson, PG; Schjesvold, FH; Sonneveld, P; Thuresson, M1

Trials

2 trial(s) available for pomalidomide and melflufen

ArticleYear
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
    Future oncology (London, England), 2020, Volume: 16, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide

2020
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
    The Lancet. Haematology, 2022, Volume: 9, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide

2022

Other Studies

1 other study(ies) available for pomalidomide and melflufen

ArticleYear
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
    Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Follow-Up Studies; Humans; Melphalan; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Assessment; Transplantation, Autologous

2023